Graham Abra, MD

Nephrologist @StanfordNeph, Chair @HDAE_Official, Director Social Media @HemodialysisInt, Defender of the 4 nephrons.

[Jen Bergeron @DrJennyBee]

Sharing my google spreadsheet of all the US Nephrology Fellowship Programs. It is a compilation of publicly available databases to show their size, transplant numbers, sub-subspecialities, and self-reported percentage of IMG/DO students the last 5 years.
https://t.co/1PzGl9Mg7l

[Graham Abra, MD @GrahamAbra]

Very well written perspective

Like the clarity this proposed naming convention offers

https://t.co/OyoYgQiAji

[Graham Abra, MD @GrahamAbra]

@eric_weinhandl @kidney_boy If not this one, I saw the Center for Dialysis Innovation group present a similar concept a few years back

Tough times

[Graham Abra, MD @GrahamAbra]

@eric_weinhandl @kidney_boy Want this one of the prior Northwest Kidney Center for Dialysis Innovation projects?

[Graham Abra, MD @GrahamAbra]

@sijiezheng @kidneybiz @Official_VeraTx A good question for all the new agents.

We have generally been able to get access to all the new FDA approved IgAN drugs through a combination of insurance coverage and pharmaceutical company patient assistance programs without excessive pt copays.

How is KP handling this?

[Graham Abra, MD @GrahamAbra]

Congrats to @kidneybiz and the team @Official_VeraTx!

Yet another option for IgA Nephropathy!

[Vera Therapeutics @Official_VeraTx]

Today, the @US_FDA granted accelerated approval to Vera Therapeutics’ therapy in #IgANephropathy (#IgAN).

Read the press release here: https://t.co/sSBve6t7rv

[Graham Abra, MD @GrahamAbra]

Rather than expecting that all pts can fxn at the level of sophistication needed for sick day med rules perhaps instructing pts to call the kidney clinic RN help line when they have a GI/volume depleting illness and only using sick day med rules for the most proactive/engaged

[Graham Abra, MD @GrahamAbra]

Sick Day Med Rules make intuitive sense but are tough to blanket implement

The complexity of this issue is further compounded by the once weekly dosing of SQ GLP1 RAs and the mild GI symptoms that can accompany use

[AJKD @AJKDonline]

Perspective by Sumeska Thavarajah:

To Hold or Not to Hold, That is the Question: Sick Day Medication Guidance as Routine Care

https://t.co/A7SOhYqZsn #OpenAccess

@hopkinsneph

[Daniel G. Fuster @Dan_Fuster]

New hope for people with kidney stones: The EMPASTONE trial launched yesterday with enrollment of the first 2 patients.
More:
https://t.co/6mYt3srivX
https://t.co/J8j0Ih6S8P

[euan ashley @euanashley]

For more than two decades, our genomics community has worked to improve the quality of genome sequencing. This has taken us from single digit numbers of human genomes to millions of genomes in 2026.

[KIReports @KIReports]

Circulating #Antinephrin Antibodies in Adult #Chinese Patients With #IgAN and Nephrotic-Range Proteinuria

#VisualAbstract by @brian_rifkin

https://t.co/zFDnvjfqQ6

[Brendon Neuen @brendonneuen]

VISIONARY trial press release: First APRIL inhibitor to demonstrate statistically significant eGFR stabilization with evidence of improvement versus placebo over two years in IgAN: https://t.co/GVRXtWGP63

[Rajiv Agarwal MD, MS @AgarwalRajivMD]

Clinical takeaway: early UACR & SBP responses are complementary, actionable signals of CV efficacy on finerenone — not just surrogate niceties. Watch both.
The other half operates through pathways still to be defined.
🔗 https://t.co/Ju6I9TN8IR
w/ @mvaduganathan @FaiezZannad

[Matthew Sparks, MD @Nephro_Sparks]

Avacopan retracted

https://t.co/YZsJ5O7ox3

[Graham Abra, MD @GrahamAbra]

@AKronbichler @BuckerGunnar Same experience here, the patients I have treated with avacopan have done well and not experienced adverse events but my n is small and critical that upfront and ongoing clinical trials be rigorous and held to the highest ethical standards

[Andreas Kronbichler @AKronbichler]

A sad day for vasculitis, patients and caregivers. A relevant tool has been taken away - however, data integrity of clinical trials is key!

Nonetheless, we need to start moving away from BVAS as endpoint! It is time …

https://t.co/lCc9pIvyBv

[Graham Abra, MD @GrahamAbra]

@eric_weinhandl Don’t fund legal trials.

Fund clinical trials!

[Eric Weinhandl @eric_weinhandl]

Do I understand all the legal mumbo jumbo in this Court of Appeals decision? No.

Despite my limitations, the decision is clear: in the case of Ardelyx vs CMS, the court has dismissed Ardelyx's complaint. Phosphate binders shall be bundled (pending the Final Rule), and tenapanor's novel MOA does not protect the drug from bundling.
https://t.co/ScvRL5Y5PJ

[Daniel Batlle @Dan_Batlle]

Thank you @CircRes for posting our paper with @polska_md, @Sweis_NWG, Meenakshi Rammohan, and Bob Rosa. I hope that it will bring attention to how intense kidney sodium chloride retention is with dietary potassium deprivation, and therefore, the importance of avoiding low-potassium diets to prevent hypertension and cardiovascular disease.

@NUFeinbergMed
@NU_Nephrology
@NorthwesternMed

[Brendon Neuen @brendonneuen]

Risk-based combination therapy in CKD - our latest state of the art review

Part of the CJASN CKM series, but broadly applicable to other forms of CKD (including IgAN) as we enter an era where combination therapy offers possibility of achieving remission

https://t.co/I00HQkt0mL